Antimigraine drug interactions with serotonin receptor subtypes in human brain
- PMID: 2898916
- DOI: 10.1002/ana.410230512
Antimigraine drug interactions with serotonin receptor subtypes in human brain
Abstract
The interactions of antimigraine agents with serotonin (5-hydroxytryptamine, 5-HT) receptor subtypes were analyzed in human frontal cortex membranes. The drugs studied included 5-HT antagonists, beta-adrenergic antagonists, and calcium channel blockers. At 5-HT1A sites labeled by 3H-8-hydroxy-2-(N,N-dipropylamino)-tetralin, (-)pindolol, alprenolol, (-)propranolol, methysergide, cyproheptadine, and pizotifen are similar in that they display affinities of approximately 100 nM for this receptor. By contrast, only methysergide displays relatively high affinity (120 +/- 60 nM), whereas all other drugs have affinities greater than 1,000 nM for non-5-HT1A sites labeled by 3H-5-HT in human cortex. Finally, at 5-HT2 receptors labeled by 3H-spiperone, cyproheptadine, methysergide, and pizotifen are extremely potent agents (affinity constants of 1 to 10 nM), whereas amitriptyline (23 +/- 4 nM), verapamil (140 +/- 50 nM), and nifedipine (320 +/- 80 nM) are moderately potent. All other drugs are inactive at concentrations below 1,000 nM. These data demonstrate that most antimigraine drugs display high affinity for the 5-HT1A and/or 5-HT2 receptor subtypes in human brain. However, antimigraine efficacy cannot be explained by drug interactions with a single 5-HT receptor subtype.
Similar articles
-
Antimigraine drug interactions with 5-hydroxytryptamine1A receptors.Ann Neurol. 1986 May;19(5):511-3. doi: 10.1002/ana.410190518. Ann Neurol. 1986. PMID: 2940961
-
Developments in 5-hydroxytryptamine receptor pharmacology in migraine.Neurol Clin. 1990 Nov;8(4):829-39. Neurol Clin. 1990. PMID: 2259314 Review.
-
Determination of selective and nonselective compounds for the 5-HT 1A and 5-HT 1B receptor subtypes in rat frontal cortex.J Pharmacol Exp Ther. 1984 Dec;231(3):480-7. J Pharmacol Exp Ther. 1984. PMID: 6502510
-
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.Mol Pharmacol. 1996 Dec;50(6):1567-80. Mol Pharmacol. 1996. PMID: 8967979
-
Multiple serotonin receptors and their physiological significance.Fed Proc. 1983 Feb;42(2):213-7. Fed Proc. 1983. PMID: 6337063 Review.
Cited by
-
Sustained Hypoxia Elicits Competing Spinal Mechanisms of Phrenic Motor Facilitation.J Neurosci. 2016 Jul 27;36(30):7877-85. doi: 10.1523/JNEUROSCI.4122-15.2016. J Neurosci. 2016. PMID: 27466333 Free PMC article.
-
Current and prospective pharmacological targets in relation to antimigraine action.Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94. doi: 10.1007/s00210-008-0322-7. Epub 2008 Jul 15. Naunyn Schmiedebergs Arch Pharmacol. 2008. PMID: 18626630 Review.
-
Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors.Naunyn Schmiedebergs Arch Pharmacol. 1992 Jul;346(1):4-11. doi: 10.1007/BF00167563. Naunyn Schmiedebergs Arch Pharmacol. 1992. PMID: 1407003
-
Analysis of the effects of a tricyclic antidepressant on secondary sleep disturbance induced by chronic pain in a preclinical model.PLoS One. 2020 Dec 3;15(12):e0243325. doi: 10.1371/journal.pone.0243325. eCollection 2020. PLoS One. 2020. PMID: 33270791 Free PMC article.
-
European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 2: flunarizine.J Headache Pain. 2023 Sep 19;24(1):128. doi: 10.1186/s10194-023-01657-3. J Headache Pain. 2023. PMID: 37723437 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical